Risk of audiologic side effects with teprotumumab treatment for thyroid eye disease: propensity matched analysis.

IF 2.8 3区医学 Q1 OPHTHALMOLOGY

Eye Pub Date : 2024-12-12 DOI:10.1038/s41433-024-03531-1

Jonathan C Markle, Anil Johanis, Jacqueline K Shaia, Daniel Benito, Katherine E Talcott, Rishi P Singh

{"title":"Risk of audiologic side effects with teprotumumab treatment for thyroid eye disease: propensity matched analysis.","authors":"Jonathan C Markle, Anil Johanis, Jacqueline K Shaia, Daniel Benito, Katherine E Talcott, Rishi P Singh","doi":"10.1038/s41433-024-03531-1","DOIUrl":null,"url":null,"abstract":"Background/objectives: Patients with thyroid eye disease (TED) taking teprotumumab have reported audiologic symptoms as a side effect; however, limited real world data and large sample sizes have been utilized to evaluate this relationship.Methods: A retrospective cohort study was created in TriNetX to identify patients with TED utilizing ICD-10, CPT, and Healthcare Common Procedure coding systems. TED patients with and without teprotumumab treatment were analysed with greedy one-to-one propensity matching. Appearance of one or more new ICD-10 codes corresponding to audiologic outcomes of interest (tinnitus, sensorineural hearing loss, hypoacusis, hyperacusis, autophony, Eustachian tube dysfunction) served as the outcome of interest. Patients with a history of hearing impairment were also evaluated for worsening hearing loss after initiation of teprotumumab.Results: Within the entire TriNetX cohort, 88 out of 441 patients with a diagnosis code for TED treated with teprotumumab had new appearance of an audiologic outcome within TriNetX. After matching, the relative risk for TED patients who were exposed to teprotumumab for new audiologic symptoms was increased with a risk ratio (RR) of 2.85 [95% CI 1.94, 4.20] compared to TED patients not exposed to teprotumumab. Of 51 patients with a history of hearing impairment and TED, 14 had record of new audiologic testing after teprotumumab administration (RR = 1.90 [0.96, 3.78]) compared to unexposed patients.Conclusions: This study affirms previous research stating that TED patients receiving teprotumumab are at an increased risk of new audiologic side effects when compared to TED patients not using teprotumumab.","PeriodicalId":12125,"journal":{"name":"Eye","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Eye","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41433-024-03531-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/objectives: Patients with thyroid eye disease (TED) taking teprotumumab have reported audiologic symptoms as a side effect; however, limited real world data and large sample sizes have been utilized to evaluate this relationship.

Methods: A retrospective cohort study was created in TriNetX to identify patients with TED utilizing ICD-10, CPT, and Healthcare Common Procedure coding systems. TED patients with and without teprotumumab treatment were analysed with greedy one-to-one propensity matching. Appearance of one or more new ICD-10 codes corresponding to audiologic outcomes of interest (tinnitus, sensorineural hearing loss, hypoacusis, hyperacusis, autophony, Eustachian tube dysfunction) served as the outcome of interest. Patients with a history of hearing impairment were also evaluated for worsening hearing loss after initiation of teprotumumab.

Results: Within the entire TriNetX cohort, 88 out of 441 patients with a diagnosis code for TED treated with teprotumumab had new appearance of an audiologic outcome within TriNetX. After matching, the relative risk for TED patients who were exposed to teprotumumab for new audiologic symptoms was increased with a risk ratio (RR) of 2.85 [95% CI 1.94, 4.20] compared to TED patients not exposed to teprotumumab. Of 51 patients with a history of hearing impairment and TED, 14 had record of new audiologic testing after teprotumumab administration (RR = 1.90 [0.96, 3.78]) compared to unexposed patients.

Conclusions: This study affirms previous research stating that TED patients receiving teprotumumab are at an increased risk of new audiologic side effects when compared to TED patients not using teprotumumab.

查看原文本刊更多论文

teprotumumab治疗甲状腺眼病的听力学副作用风险：倾向匹配分析

背景/目的：甲状腺眼病（TED）患者服用teprotumumab有听力学症状作为副作用；然而，有限的真实世界数据和大样本量被用来评估这种关系。方法：在TriNetX中建立了一项回顾性队列研究，利用ICD-10、CPT和医疗保健通用程序编码系统识别TED患者。采用贪婪的一对一倾向匹配对接受和未接受teprotumumab治疗的TED患者进行分析。出现与感兴趣的听力学结果（耳鸣、感音神经性听力损失、听觉减退、听觉亢进、自音、耳咽管功能障碍）相对应的一个或多个新的ICD-10编码作为感兴趣的结果。有听力损害史的患者也在开始teprotumumab治疗后评估听力损失的恶化。结果：在整个TriNetX队列中，441例诊断代码为TED的患者中有88例接受teprotumumab治疗，在TriNetX中出现了听力学结果的新表现。匹配后，与未暴露于teprotumumab的TED患者相比，暴露于teprotumumab的TED患者出现新的听力学症状的相对风险增加，风险比（RR）为2.85 [95% CI 1.94, 4.20]。在51例有听力障碍和TED病史的患者中，与未使用teprotumumab的患者相比，14例在给予teprotumumab后有新的听力学检查记录（RR = 1.90[0.96, 3.78]）。结论：本研究证实了先前的研究，即与未使用teprotumumab的TED患者相比，接受teprotumumab治疗的TED患者出现新的听力学副作用的风险增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Eye 医学-眼科学

CiteScore

6.40

自引率

5.10%

发文量

481

审稿时长

3-6 weeks

期刊介绍： Eye seeks to provide the international practising ophthalmologist with high quality articles, of academic rigour, on the latest global clinical and laboratory based research. Its core aim is to advance the science and practice of ophthalmology with the latest clinical- and scientific-based research. Whilst principally aimed at the practising clinician, the journal contains material of interest to a wider readership including optometrists, orthoptists, other health care professionals and research workers in all aspects of the field of visual science worldwide. Eye is the official journal of The Royal College of Ophthalmologists. Eye encourages the submission of original articles covering all aspects of ophthalmology including: external eye disease; oculo-plastic surgery; orbital and lacrimal disease; ocular surface and corneal disorders; paediatric ophthalmology and strabismus; glaucoma; medical and surgical retina; neuro-ophthalmology; cataract and refractive surgery; ocular oncology; ophthalmic pathology; ophthalmic genetics.